UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **PF 114 CIP**

Total Pages in this Submesion

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an										
invention entitled: USE OF THE (1S,2R) ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A DRUG										
and invented by: Jean DEREGNAUCOURT and Richard GROSSE										
If a Co	ONT	INITA	TION	ΔΡΙ	PLICATION	chac	ek appropriato ha	and oungly	the requisite information.	
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: ☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 10/453,574										
Which				_	Diviolonal	فيت	Oomanda.on-i	m-part (On)	or prior application No	10/453,574
	Conti	nuat	ion		Divisional		Continuation-i	in-part (CIP)	of prior application No.:	
Which										
	Conti	nuat	ion		Divisional		Continuation-i	in-part (CIP)	of prior application No.:	•
Enclo	sed a	re:								
							Application	n Elements		
1.	X	Filin	g fee	as c	alculated and	tran	smitted as desc	ribed below		
) 2 .	\boxtimes	Spe	cificat	ion I	naving	·	55	pages and ir	ncluding the following:	
	a.	\boxtimes	Descriptive Title of the Invention							
	b.		Cros	s Re	eferences to F	Relat	ed Applications	(if applicable)		
	c.		State	emer	nt Regarding	Fede	erally-sponsored	Research/De	velopment (if applicable)	
	d. Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix									
	e.	\boxtimes	Background of the Invention							
	f.	\boxtimes	Brief Summary of the Invention							
	g.	\boxtimes	Brief Description of the Drawings (if filed)							
	h.	\boxtimes	Detailed Description							
	i.	\boxtimes	Claim(s) as Classified Below							
	j. 🛛 Abstract of the Disclosure									

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. PF 114 CIP

Total Pages in this Submission

Application Elements (Continued)												
3.	\boxtimes	Drawing(s) (when necessary as prescribed by 35 USC 113)										
	a.	□ Sheets 4 □ Sheets 4										
	b.	☐ Informal Number of Sheets										
4.	\boxtimes	Oath or Declaration										
	a.	☐ Newly executed (original or copy) ☐ Unexecuted										
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)										
	C.											
•	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).										
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.										
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)										
7.	\boxtimes	Application Data Sheet (See 37 CFR 1.76)										
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)										
	a.	☐ Computer Readable Form (CRF)										
	b.	☐ Specification Sequence Listing on:										
		i. 🔲 CD-ROM or CD-R (2 copies); or										
		ii. 🔲 Paper										
	c.	Statement(s) Verifying Identical Paper and Computer Readable Copy										
		Accompanying Application Parts										
9.		Assignment Papers (cover sheet & document(s))										
10.		37 CFR 3.73(B) Statement (when there is an assignee)										
11.		English Translation Document (if applicable)										
12.	\boxtimes	Information Disclosure Statement/PTO-1449										
13.		Preliminary Amendment										
14.	\boxtimes	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)										
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)										
16.	\boxtimes	Certificate of Mailing										
		☐ First Class ☒ Express Mail (Specify Label No.): EV 346996404 US										

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. PF 114 CIP

Total Pages in this Submission

Accompanying Application Parts (Continued)							
17.		Additional Enclosures (please identify below):					
•							
•		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					
		Warning					
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.					
j							

À

7

TILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **PF 114 CIP**

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For #Filed #Allowed #Extra Rate Fee **Total Claims** 23 - 20 = 3 \$18.00 \$54.00 Indep. Claims 1 - 3 = 0 \$86.00 \$0.00 Multiple Dependent Claims (check if applicable) \$0.00 **BASIC FEE** \$770.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$824.00

	A check in the amount of	\$824.00	to cover the filing fee is enclosed.				
\boxtimes	The Director is hereby authorized to charge and credit Deposit Account No.						
	as described below.						
	Charge the amount of	f	as filing fee.				

☑ Credit any overpayment.

□ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

pursuant to 37 C.F.R. 1.311(b).

Dated: 22 MAR 2004

G. Patrick SAGE, #37,710 The Firm of Hueschen and Sage 500 Columbia Plaza 350 East Michigan Avenue

cc:

CUSTOMER NUMBER 25666

Kalamazoo, MI 49007

Applicant:

Jean DEREGNAUCOURT and Richard GROSSE

Title:

USE OF THE (1S,2R) ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION

OF A DRUG

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR 1.10)

Express Mail No.: EV 346996404 US Date of Deposit: 22 MAR 2004

I hereby certify that this continuation-in-part application with Specification, Claims, Drawings, unexecuted Declaration/Power of Attorney, PTO 1449, Application Data Sheet, post card receipt, and check for \$824 is being deposited with the United States Postal Service "Express Mail Post Office to Addressee Service" under 37 CFR 1.10 on the date indicated above and is addressed to the MAIL STOP PATENT APPLICATION, Commissioner of Patents and Trademarks, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

THE FIRM OF HUESCHEN AND SAGE

By: Diane L. Newton